Thura, Min http://orcid.org/0000-0002-0462-9020
Ye, Zu
Al-Aidaroos, Abdul Qader
Xiong, Qiancheng http://orcid.org/0000-0002-9897-7391
Ong, Jun Yi
Gupta, Abhishek
Li, Jie http://orcid.org/0000-0001-6404-1432
Guo, Ke
Ang, Koon Hwee
Zeng, Qi http://orcid.org/0000-0002-8940-0275
Funding for this research was provided by:
MOH | National Medical Research Council (NMRC/OFIRG/0053/2017)
Institute of Molecular & Cell Biology, Agency for Science, Technology and Research (A*STAR), Singapore - Core Fund
Article History
Received: 22 January 2021
Accepted: 13 July 2021
First Online: 29 July 2021
Change Date: 8 November 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s42003-021-02812-9
Competing interests
: The authors declare the following competing interests: Q.Z. is the founder of Intra-Immu SG Pte Ltd, a spin-off company granted licensing rights to the PRL3-zumab IP portfolio. The other authors declare no competing interests.